Vivos Therapeutics, Inc.
VVOSNasdaq
$0.42
↑ +1.6%Jul 17 close · end-of-day
Price
1Y↓ -93.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.1M
Enterprise Value
$11.7M
P/E
—
P/S
0.3
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-321.1%
Dividend Yield
—
Revenue (TTM)
$19.6M
Net Income (TTM)
-$25.0M
Free Cash Flow (TTM)
-$19.7M
Gross Margin
61.8%
Operating Margin
-115.5%
Net Margin
-127.7%
ROE
2195.8%
ROIC
-399.4%
Debt / Equity
-6.8
Net Cash
-$5.6M
Return 1Y
-92.7%
Company profile
Vivos Therapeutics, Inc. develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada.
- CEO
- R. Kirk Huntsman
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 160
- Headquarters
- Colorado
- Website
- vivos.com
Earnings
VVOS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$5.1M↑ +70.5%
Diluted EPS-$0.52↑ +15.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.1M | $16.9M | $16.0M | $13.8M | $15.0M | $17.4M |
| Gross profit | $10.4M | $12.6M | $10.0M | $8.3M | $9.0M | $10.5M |
| Operating income | -$12.0M | -$20.4M | -$25.0M | -$17.3M | -$11.2M | -$19.9M |
| Net income | -$12.1M | -$20.3M | -$23.8M | -$13.6M | -$11.1M | -$21.2M |
| Diluted EPS | — | — | -$25.90 | -$11.14 | -$2.22 | -$2.07 |
| Operating cash flow | -$5.7M | -$15.7M | -$19.6M | -$11.9M | -$12.7M | -$15.3M |
| Free cash flow | -$5.8M | -$18.1M | -$20.5M | -$12.7M | -$13.3M | -$17.6M |
| Gross margin | 79.7% | 74.6% | 62.5% | 59.9% | 60.0% | 60.4% |
| Operating margin | -92.1% | -120.7% | -156.2% | -125.3% | -74.3% | -114.1% |
| Net margin | -92.3% | -120.2% | -148.8% | -98.4% | -74.1% | -121.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $3.9M | $3.7M | $3.0M | $3.8M | $6.8M | $3.8M | $5.1M |
| Gross profit | $2.7M | $2.3M | $2.1M | $1.5M | $2.1M | $3.9M | $3.0M | $3.1M |
| Operating income | -$1.9M | -$2.6M | -$2.8M | -$3.9M | -$4.9M | -$4.7M | -$6.4M | -$6.6M |
| Net income | -$1.9M | -$2.6M | -$2.8M | -$3.9M | -$5.0M | -$5.4M | -$6.9M | -$7.7M |
| Diluted EPS | -$0.60 | -$0.40 | $0.41 | -$0.45 | -$0.55 | -$0.49 | -$0.58 | -$0.52 |
| Operating cash flow | -$3.0M | -$4.2M | -$2.9M | -$3.8M | -$3.5M | -$4.2M | -$3.8M | -$6.0M |
| Free cash flow | -$3.1M | -$4.4M | -$3.1M | -$3.9M | -$4.3M | -$4.2M | -$5.3M | -$6.0M |
| Gross margin | 65.4% | 60.5% | 56.7% | 50.0% | 55.2% | 58.0% | 78.1% | 59.5% |
| Operating margin | -47.8% | -68.5% | -75.9% | -129.9% | -127.4% | -69.8% | -166.8% | -128.7% |
| Net margin | -47.6% | -67.8% | -76.4% | -128.1% | -131.2% | -79.6% | -180.3% | -149.4% |
Company news
Jul 18, 2026
Jun 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-31 | Skaff Michael C | Buy | 1,044,777 | $1.34 | $1.4M | filing |
| 2026-03-31 | Skaff Michael C | Buy | 308,848 | $1.34 | $413,856.32 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.